SANOCHEMIA Pharmazeutika GmbH
Landegger Straße 7 und 33 A-2491
Neufeld an der Leitha

Wide range of services

Because we put quality first

With the development, production and distribution of pharmaceutical specialties, we have been contributing to people’s health for more than 30 years. Our strengths include the development and manufacture of sterile liquid dosage forms and small molecule active pharmaceutical ingredients. For our own needs and as CDMO for third parties.

Imaging Agents

In Austria, we develop, produce and distribute some of the most established generic imaging agents under the Sanochemia brand. Our products help physicians make efficient therapeutic decisions for patients.

Contract Manufacturing

With contract manufacturing of sterile and low-bioburden liquids as well as APIs, we offer in-depth expertise in the field of drug product and API production. As a full-service provider, we also support with GMP services.

API

Our focus on high-quality API synthesis completes our “made in Austria” offering. Innovative APIs for the treatment of muscle spasms and Alzheimer’s disease are produced and distributed by Sanochemia.

TRUSTED PARTNER
FOR THE PHARMACEUTICAL INDUSTRY
Pharmaceutical specialties from Austria
We put our customers first. Are you looking for a
competent partner for your drug product or active ingredient production?
Always remain up to date
Sanochemia receives ALC Inclusion Award

Sanochemia receives ALC Inclusion Award

In October 2025, Sanochemia Pharmazeutika was honored with the Austrian Leading Companies (ALC) Inclusion Award. This recognition highlights the company’s longstanding commitment to fostering diversity, equal opportunities, and accessibility in the workplace.

Read more
1200 450 Sanochemia
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Also Secondary Endpoints in Phase III

Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Also Secondary Endpoints in Phase III

The multicentric prospective PROSTAPROGRESS study on Ferumoxtran confirmed to meet also secondary endpoints. Post-hoc analysis showed elevated sensitivity and specificity data for metastatic lymph node lesions at levels surpassing the levels of current technologies.

Read more
1200 450 Sanochemia
Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study
Signing Ferrotran ECR 2024 Sanochemia

Sanochemia/SPL: Investigational Iron-Based MRI Contrast Agent Meets Primary Endpoints in Pivotal Phase III Study

Neufeld, Austria, February 25th, 2025 – Sanochemia Pharmazeutika today announced positive headline results of the…

Read more
1200 450 Sanochemia